Overexpression of S100A14 in human serous ovarian carcinoma

Qian,Jingfeng; Ding,Fang; Luo,Aiping; Liu,Zhihua; Cui,Zhumei

doi:10.3892/ol.2015.3984

Overexpression of S100A14 in human serous ovarian carcinoma

Authors:
- Jingfeng Qian
- Fang Ding
- Aiping Luo
- Zhihua Liu
- Zhumei Cui
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Affiliated Hospital of Qingdao University, Qingdao, Shandong 266061, P.R. China, State Key Laboratory of Molecular Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P.R. China
Published online on: December 1, 2015 https://doi.org/10.3892/ol.2015.3984
Pages: 1113-1119

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

S100 calcium binding protein A14 (S100A14) is a member of the S100 protein family that plays an important role in the progression of several types of cancer. In the present study, the expression and clinical effect of S100A14 was evaluated in serous ovarian carcinoma (SOC). SOC tissue specimens and a panel of normal ovarian and fallopian tubal tissue specimens were obtained between November 2008 and August 2012 from the Affiliated Hospital of Qingdao University. Immunohistochemistry (IHC) was used to detect the expression of S100A14 in the SOC and normal control tissues. In addition, ELISA was performed to assess S100A14 expression in a subset of serum samples. The association between the expression of S100A14 in SOC and the corresponding clinical and pathological data was analyzed. The IHC results revealed that S100A14 was mainly located in the cytoplasm of the majority of SOC cells, and the expression levels of S100A14 in the tumor tissues were significantly increased compared with the levels identified in normal ovarian specimens (P<0.001). Consistently, the serum levels of S100A14 in patients with SOC were also increased compared with the levels in healthy individuals (P<0.001). S100A14 expression was similar in the epithelium of SOC lesions and the fallopian tube, which supported the dualistic model for ovarian serous carcinogenesis. Additional analysis of the expression of S100A14 and corresponding clinical and pathological data revealed the correlation between the elevated expression of S100A14 and resistance to platinum‑based chemotherapy. However, the protein level of S100A14 was not associated with the pathological stage, differentiation or metastasis of SOC. Overall, the present results demonstrate that S100A14 is likely to be involved in the resistance of SOC to platinum-based chemotherapy.

View Figures

View References

1	Singh AP, Senapati S, Ponnusamy MP, et al: Clinical potential of mucins in diagnosis, prognosis and therapy of ovarian cancer. Lancet Oncol. 9:1076–1085. 2008. View Article : Google Scholar : PubMed/NCBI
2	Lin KT, Yeh YM, Chuang CM, Yang SY, Chang JW, Sun SP, Wang YS, Chao KC and Wang LH: Glucocorticoids mediate induction of microRNA-708 to suppress ovarian cancer metastasis through targeting Rap1B. Nat Commun. 6:59172015. View Article : Google Scholar : PubMed/NCBI
3	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
4	Chen W, Zheng R, Zhang S, Zhao P, Li G, Wu L and He J: The incidences and mortalities of major cancers in China, 2009. Chin J Cancer. 32:106–112. 2013. View Article : Google Scholar : PubMed/NCBI
5	Chen W, Zheng R, Zhang S, Zhao P, Li G, Wu L and He J: Report of incidence and mortality in China cancer registries, 2009. Chin J Cancer Res. 25:10–21. 2013.PubMed/NCBI
6	Gubbels JA, Claussen N, Kapur AK, Connor JP and Patankar MS: The detection, treatment, and biology of epithelial ovarian cancer. J Ovarian Res. 3:82010. View Article : Google Scholar : PubMed/NCBI
7	Schummer M, Ng WV, Bumgarner RE, Nelson PS, Schummer B, Bednarski DW, Hassell L, Baldwin RL, Karlan BY and Hood L: Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene. 238:375–385. 1999. View Article : Google Scholar : PubMed/NCBI
8	Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Aghajanian C, Barakat RR and Chi DS: The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecol Oncol. 108:276–281. 2008. View Article : Google Scholar : PubMed/NCBI
9	Barger CJ, Zhang W, Hillman J, Stablewski AB, Higgins MJ, Vanderhyden BC, Odunsi K and Karpf AR: Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression. Oncotarget. 6:27613–27627. 2015. View Article : Google Scholar : PubMed/NCBI
10	Singer G, Kurman RJ, Chang HW, Cho SK and Shih IeM: Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol. 160:1223–1228. 2002. View Article : Google Scholar : PubMed/NCBI
11	Kuhn E, Kurman RJ, Vang R, Sehdev AS, Han G, Soslow R, Wang TL and Shih IeM: TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma-evidence supporting the clonal relationship of the two lesions. J Pathol. 226:421–426. 2012. View Article : Google Scholar : PubMed/NCBI
12	Heizmann CW, Fritz G and Schäfer BW: S100 proteins Structure, functions and pathology. Front Biosci. 7:d1356–d1368. 2002. View Article : Google Scholar : PubMed/NCBI
13	Schäfer BW, Wicki R, Engelkamp D, Mattei MG and Heizmann CW: Isolation of a YAC clone covering a cluster of nine S100 genes on human chromosome 1q21: Rationale for a new nomenclature of the S100 calcium-binding protein family. Genomics. 25:638–643. 1995. View Article : Google Scholar : PubMed/NCBI
14	Weterman MA, Wilbrink M and Dijkhuizen T: van denB erg E and Geurts van Kessel A: Fine mapping of the 1q21 breakpoint of the papillary renal cell carcinoma-associated (X;1) translocation. Hum Genet. 98:16–21. 1996. View Article : Google Scholar : PubMed/NCBI
15	Gendler SJ, Cohen EP, Craston A, Duhig T, Johnstone G and Barnes D: The locus of the polymorphic epithelial mucin (PEM) tumour antigen on chromosome 1q21 shows a high frequency of alteration in primary human breast tumours. Int J Cancer. 45:431–435. 1990. View Article : Google Scholar : PubMed/NCBI
16	Bresnick AR, Weber DJ and Zimmer DB: S100 proteins in cancer. Nat Rev Cancer. 15:96–109. 2015. View Article : Google Scholar : PubMed/NCBI
17	Huttunen HJ, Kuja-Panula J, Sorci G, Agneletti AL, Donato R and Rauvala H: Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation. J Biol Chem. 275:40096–40105. 2000. View Article : Google Scholar : PubMed/NCBI
18	Filipek A, Jastrzebska B, Nowotny M and Kuznicki J: CacyBP/SIP, a calcyclin and Siah-1-interacting protein, binds EF-hand proteins of the S100 family. J Biol Chem. 277:28848–28852. 2002. View Article : Google Scholar : PubMed/NCBI
19	Arumugam T, Simeone DM, Schmidt AM and Logsdon CD: S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE). J Biol Chem. 279:5059–5065. 2004. View Article : Google Scholar : PubMed/NCBI
20	Fernandez-Fernandez MR, Veprintsev DB and Fersht AR: Proteins of the S100 family regulate the oligomerization of p53 tumor suppressor. Proc Natl Acad Sci USA. 102:4735–4740. 2005. View Article : Google Scholar : PubMed/NCBI
21	Zhang HY, Zheng XZ, Wang XH, Xuan XY, Wang F and Li SS: S100A4 mediated cell invasion and metastasis of esophageal squamous cell carcinoma via the regulation of MMP-2 and E-cadherin activity. Mol Biol Rep. 39:199–208. 2012. View Article : Google Scholar : PubMed/NCBI
22	Donato R: S100: A multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol. 33:637–668. 2001. View Article : Google Scholar : PubMed/NCBI
23	Zimmer DB, Cornwall EH, Landar A and Song W: The S100 protein family, History, function and expression. Brain Res Bull. 37:417–429. 1995. View Article : Google Scholar : PubMed/NCBI
24	Pietas A, Schlüns K, Marenholz I, Schafer BW, Heizmann CW and Petersen I: Molecular cloning and characterization of the human S100A14 gene encoding a novel member of the S100 family. Genomics. 79:513–522. 2002. View Article : Google Scholar : PubMed/NCBI
25	Chen H, Yu D, Luo A, Tan W, Zhang C, Zhao D, Yang M, Liu J, Lin D and Liu Z: Functional role of S100A14 genetic variants and their association with esophageal squamous cell carcinoma. Cancer Res. 69:3451–3457. 2009. View Article : Google Scholar : PubMed/NCBI
26	Xu C, Chen H, Wang X, Gao J, Che Y, Li Y, Ding F, Luo A, Zhang S and Liu Z: S100A14, a member of EF-hand calcium-binding proteins, is overexpressed in breast cancer and acts as a modulator of HER2 signaling. J Biol Chem. 289:827–837. 2014. View Article : Google Scholar : PubMed/NCBI
27	Leth-Larsen R, Terp MG, Christensen AG, Elias D, Kühlwein T, Jensen ON, Petersen OW and Ditzel HJ: Functional heterogeneity within the CD44 high human breast cancer stem cell-like compartment reveals a gene signature predictive of distant metastasis. Mol Med. 18:1109–1121. 2012. View Article : Google Scholar : PubMed/NCBI
28	Wang HY, Zhang JY, Cui JT, Tan XH, Li WM, Gu J and Lu YY: Expression status of S100A14 and S100A4 correlates with metastatic potential and clinical outcome in colorectal cancer after surgery. Oncol Rep. 23:45–52. 2010.PubMed/NCBI
29	Chen H, Yuan Y, Zhang C, Luo A, Ding F, Ma J, Yang S, Tian Y, Tong T, Zhan Q and Liu Z: Involvement of S100A14 protein in cell invasion by affecting expression and function of matrix metalloproteinase (MMP)-2 via p53-dependent transcriptional regulation. J Biol Chem. 287:17109–17119. 2012. View Article : Google Scholar : PubMed/NCBI
30	Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, Sharma R, Stewart C, Fereday S, Caldas C, Defazio A, et al: Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol. 221:49–56. 2010. View Article : Google Scholar : PubMed/NCBI
31	Cancer Genome Atlas Research Network: Integrated genomic analyses of ovarian carcinoma. Nature. 474:609–615. 2011. View Article : Google Scholar : PubMed/NCBI
32	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
33	Farley J, Ozbun LL and Birrer MJ: Genomic analysis of epithelial ovarian cancer. Cell Res. 18:538–548. 2008. View Article : Google Scholar : PubMed/NCBI
34	Karst AM and Drapkin R: Ovarian cancer pathogenesis: A model in evolution. J Oncol. 2010:9323712010. View Article : Google Scholar : PubMed/NCBI
35	Katano M, Okamoto K, Suematsu N, Kurokawa MS, Nakamura H, Masuko K, Yudoh K and Kato T: Increased expression of S100 calcium binding protein A8 in GM-CSF-stimulated neutrophils leads to the increased expressions of IL-8 and IL-16. Clin Exp Rheumatol. 29:768–775. 2011.PubMed/NCBI
36	Grebhardt S, Veltkamp C, Ströbel P and Mayer D: Hypoxia and HIF-1 increase S100A8 and S100A9 expression in prostate cancer. Int J Cancer. 131:2785–2794. 2012. View Article : Google Scholar : PubMed/NCBI
37	Foell D, Seeliger S, Vogl T, Koch HG, Maschek H, Harms E, Sorg C and Roth J: Expression of S100A12 (EN-RAGE) in cystic fibrosis. Thorax. 58:613–617. 2003. View Article : Google Scholar : PubMed/NCBI
38	Matsunaga H and Ueda H: Evidence for serum-deprivation-induced co-release of FGF-1 and S100A13 from astrocytes. Neurochem Int. 49:294–303. 2006. View Article : Google Scholar : PubMed/NCBI
39	Leite MC, Galland F, de Souza DF, Guerra MC, Bobermin L, Biasibetti R, Gottfried C and Gonçalves CA: Gap junction inhibitors modulate S100B secretion in astrocyte cultures and acute hippocampal slices. J Neurosci Res. 87:2439–2446. 2009. View Article : Google Scholar : PubMed/NCBI
40	Li R, Xia W, Zhang Z and Wu K: S100B protein, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor in human milk. PLoS One. 6:e216632011. View Article : Google Scholar : PubMed/NCBI
41	Zhang H, Zhao Q, Chen Y, Wang Y, Gao S, Mao Y, Li M, Peng A, He D and Xiao X: Selective expression of S100A7 in lung squamous cell carcinomas and large cell carcinomas but not in adenocarcinomas and small cell carcinomas. Thorax. 63:352–359. 2008. View Article : Google Scholar : PubMed/NCBI
42	Hermani A, Hess J, De Servi B, Medunjanin S, Grobholz R, Trojan L, Angel P and Mayer D: Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer. Clin Cancer Res. 11:5146–5152. 2005. View Article : Google Scholar : PubMed/NCBI
43	Martenson ED, Hansson LO, Nilsson B, von Schoultz E, Månsson Brahme E, Ringborg U and Hansson J: Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma. J Clin Oncol. 19:824–831. 2001.PubMed/NCBI
44	Jin Q, Chen H, Luo A, Ding F and Liu Z: S100A14 stimulates cell proliferation and induces cell apoptosis at different concentrations via receptor for advanced glycation end products (RAGE). PLoS One. 6:e193752011. View Article : Google Scholar : PubMed/NCBI
45	Kaku T, Ogawa S, Kawano Y, Ohishi Y, Kobayashi H, Hirakawa T and Nakano H: Histological classification of ovarian cancer. Med Electron Microsc. 36:9–17. 2003. View Article : Google Scholar : PubMed/NCBI
46	Smith S, Su D, de la Longrais Rigault IA, Schwartz P, Puopolo M, Rutherford TJ, Mor G, Yu H and Katsaros D: ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy. J Clin Oncol. 25:5172–5179. 2007. View Article : Google Scholar : PubMed/NCBI
47	Krivak TC, Darcy KM, Tian C, Armstrong D, Baysal BE, Gallion H, Ambrosone CB and De Loia JA: Gynecologic Oncology Group Phase III Trial. Relationship between ERCC1 polymorphisms, disease progression and survival in the gynecologic oncology group phase III trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer. J Clin Oncol. 26:3598–3606. 2008. View Article : Google Scholar : PubMed/NCBI
48	Colombo PE, Fabbro M, Theillet C, Bibeau F, Rouanet P and Ray-Coquard I: Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer. Crit Rev Oncol Hematol. 89:207–216. 2014. View Article : Google Scholar : PubMed/NCBI
49	Angioli R, Capriglione S, Aloisi A, Guzzo F, Luvero D, Miranda A, Damiani P, Montera R, Terranova C and Plotti F: Can HE4 predict platinum response during first-line chemotherapy in ovarian cancer? Tumour Biol. 35:7009–7015. 2014. View Article : Google Scholar : PubMed/NCBI